2013 CME Annual Meeting in MS: How to translate new insights in MS into clinical practice


Published on

Published in: Health & Medicine, Education
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

2013 CME Annual Meeting in MS: How to translate new insights in MS into clinical practice

  1. 1. 2013 CME Annual meeting in multiple sclerosisHow to translate new insightsin MS into clinical practiceIstanbul, Turkey - 31 May - 1 June, 2013PRELIMINARY PROGRAMME
  2. 2. 1Welcome noteDavid BatesChairmanNewcastle upon Tyne, UKMagnhild Sandberg-WollheimCo-ChairLund, SwedenDear Colleague,On behalf of the Serono Symposia International Foundation, it is our pleasure to welcome you to the 2013 annual continuing medical education(CME)-accredited meeting: “How to translate new insights in MS into clinical practice”. At this live educational conference, leading internationalexperts will share cutting-edge research on the pathogenesis and treatment of multiple sclerosis (MS) and discuss how best to incorporate ourknowledge into the everyday treatment of patients. You will also have the opportunity to earn CME credits.This live educational conference will consist of six interactive sessions. Session I will cover current diagnostic methodology, with advice on how toensure an accurate and timely diagnosis, and how best to communicate with the patient at this time. In Session II we will detail the rapidly increasingrange of treatment options for MS, and in Session III, discuss how these treatments might be best worked into useful treatment algorithms. SessionIV will detail the current understanding of brain plasticity and recovery and repair processed in MS, and how these processes might be promotedthrough treatment. In Session V, presenters will detail the latest research into genetic aspects of MS, and comment on how the findings of thisresearch may affect clinical practice. The final session of the meeting, Session VI, will focus on what is known about childhood MS and how best toapproach the treatment of paediatric MS.Case studies will be presented in each session, offering you the opportunity to discuss various aspects of clinical practice with the panel of experts.The aims of the 2013 annual conference are: to help learners apply the latest diagnostic tools to achieve a prompt MS diagnosis; to offer objectivecomparisons of different therapeutic options and identify the most suitable drug for individualized treatment; to review new insights on the geneticsand proteomics behind MS; and to facilitate the identification and treatment of juvenile MS.This diverse programme will provide state-of-the-art information for clinicians on current research as well as practical adviceon patient management.We hope that you will be able to join us and take part in what we anticipate will be lively discussions.Yours sincerely,
  3. 3. 2Learning objectivesTarget audienceAim of the conferenceBy attending this live educational conference,learners will be able to:• Apply the diagnostic tools to achieve a promptMS diagnosis;• Compare different therapeutic options and identifythe most suitable drug for individualized treatment;• Review the new insights about genetics and proteomics;• Identify different forms of the juvenile MS to applythe right therapeutic intervention.Clinicians involved in MS management.New data emerging from imaging, pharmacogenomic andgenetic studies have expanded our understanding aboutMultiple Sclerosis (MS), making the management morecomplex and changing the way in which MS is treated.In this complex scenario, the 2013 Annual meeting will givethe learners the opportunity to learn more about how to applythe diagnostic tools to achieve a prompt MS diagnosis and howto choose the best therapeutic intervention, in order to limitinflammatory damage in the early stages of the disease andto enhance the recovery processes and brain plasticity.Moreover, the learners will be updated about the new insightin genetics and pharmacogenomics to learn how to translateknowledge into practice and improve MS managementin the daily practice. To address to the hottest topic in MS,the meeting will give also an overview on juvenile MS, guidinglearners through the diagnosis and therapeutic options for thisparticular and interesting subset of patients.
  4. 4. Serono Symposia International Foundation (www.seronosymposia.org) is accreditedby the European Accreditation Council for Continuing Medical Education (EACCME®)to provide the following CME activity for medical specialists. The EACCME®is aninstitution of the European Union of Medical Specialists (UEMS), www.uems.net.The 2013 CME Annual Meeting in Multiple Sclerosis: “How to translate new insightsin MS into clinical practice” to be held in Istanbul, Turkey on 31 May - 1 June 2013,is designated for a maximum of 9 (nine) hours of European CME credits (ECMEC).Each medical specialist should claim only those credits that he/she actually spent inthe educational activity. EACCME®credits are recognized by the American MedicalAssociation towards the Physician’s Recognition Award (PRA). To convert EACCME®credit to AMA PRA category 1 credit, please contact the AMA.AccreditationGoodCME PracticeSerono Symposia International Foundation adheres to the principlesof the Good CME Practice group3
  5. 5. 4Scientific organizersChairDavid BatesDepartment of NeurologyRoyal Victoria InfirmaryNewcastle upon Tyne, UKCo-ChairMagnhild Sandberg-WollheimDepartment of NeurologyLund University HospitalLund, SwedenScientific SecretariatSerono SymposiaInternational FoundationSalita San Nicola da Tolentino, 1/B00187 Rome, ItalyNeurology team leader:Serena Dell’AricciaProject manager:Alessia AddessiMedical advisor:Federica CerriPhone: +39 06 420 413 591Fax: +39 06 420 413 677info@seronosymposia.orgOrganizing SecretariatMeridiano Congress InternationalVia Mentana, 2/B00185 Rome, ItalyCongress coordinator:Federica RussettiPhone: +39 06 88 595 209f.russetti@meridiano.itAll Serono Symposia International Foundation programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted.All Serono Symposia International Foundation programmes are made possible thanks to educational grants received from: Arseus Medical, Besins Healthcare, Bristol-Myers Squibb, Celgene, Centre d’EsclerosiMultiple de Catalunya (Vall d’Hebron University Hospital), Centre Hépato-Biliaire, Hôpital Paul Brousse, ComtecMed, Congrex, Croissance Conseil, Cryo-Save, Datanalysis, Dos33, Esaote, European Society ofEndocrinology, Ferring, Fondazione Humanitas, Fundación IVI, GE Healthcare, GlaxoSmithKline Pharmaceuticals, IPSEN, Johnson & Johnson Medical, ISFP International Society for Fertility Preservation, ISMHInternational Society of Men’s Health, K.I.T.E., Karl Storz, Lumenis, Merck Serono Group, PregLem, Richard Wolf Endoscopie, Sanofi-Aventis, Stallergenes, Stopler, Teva Pharma, Toshiba Medical Systems,Université Catholique de Louvain (UCL), University of Catania.
  6. 6. 5List of faculty membersMarco BacigaluppiNeuroimmunology Unit Departmentof NeurologyInstitute of Experimental NeurologyVita-Salute San Raffaele UniversityMilan, ItalyDavid BatesDepartment of Neurology Royal VictoriaInfirmaryNewcastle upon Tyne, UKGiancarlo ComiDepartment of Neurology Instituteof Experimental NeurologyVita-Salute San Raffaele UniversityMilan, ItalyAngelo GhezziMultiple Sclerosis CentreGallarate HospitalGallarate, ItalyGavin GiovannoniDepartment of Neurology The RoyalLondon HospitalWhitechapel, London, UKDouglas GoodinUCSF Multiple Sclerosis CenterUniversity of California San FranciscoSan Francisco, CA, USADavid HaflerDepartment of Neurology Yale Schoolof MedicineNew Haven, Connecticut, USAHans-Peter HartungDepartment of NeurologyHeinrich-Heine-UniversityDüsseldorf, GermanyLudwig KapposDepartment of Biomedicine UniversityHospital BaselBasel, SwitzerlandRana KarabudakHacettepe University HospitalDeptartment of NeurologyNeuroimmunology UnitAnkara, TurkeyBernd KieseierDepartment of NeurologyHeinrich-Heine UniversityDüsseldorf, GermanyJeffrey KleimSchool of Biological and HealthSystems EngineeringArizona State UniversityTempe, USADawn LangdonDepartment of Psychology Royal HollowayUniversity of LondonLondon, UKXavier MontalbanMultiple Sclerosis Center of CataloniaUnit of Clinical NeuroimmunologyVall d’Hebron University HospitalBarcelona, SpainJorge OksenbergDepartment of Neurology Universityof California at San Francisco (UCSF)San Francisco, USAPeter RieckmannBamberg Hospital and Universityof ErlangeBamberg, GermanyMagnhild Sandberg-WollheimDepartment of NeurologyLund University HospitalLund, SwedenAksel SivaDepartment of NeurologyIstanbul UniversityIstanbul, TurkeyMaria Pia SormaniUniversity of GenoaGenoa, ItalyElia StupkaUnit Center for Translational Genomicsand BioinformaticsSan Raffaele Scientific InstituteMilan, ItalySilvia TenembaumDepartment of Neurology NationalPediatric Hospital “Dr. Juan Garrahan”Buenos Aires, ArgentinaAlan J. ThompsonDepartment of Brain Repair andRehabilitation Institute of NeurologyUniversity College London NationalHospital for Neurology and NeurosurgeryLondon, UKAnn YehDivision of NeurologyHospital for Sick ChildrenToronto, CanadaTjalf ZiemssenMS center Dresden NeurologicalUniversity ClinicDresden, Germany
  7. 7. Scientificprogramme
  8. 8. 8Friday, 31 MaySESSION I MS before MS - differential diagnosisModerators: M. Sandberg-Wollheim (Sweden) - A. Siva (Turkey)08.50 L1: Early diagnosis (RIS/CIS)X. Montalban (Spain)09.10 L2: Differential diagnosis: MS and acquireddemyelinating disordersG. Comi (Italy)09.30 L3: Mc Donald criteriaD. Bates (UK)09.50 L4: Diagnosis communicationand patients’ coping strategiesD. Langdon (UK)10.10 C1: Case studies on early diagnosisand differential diagnosisG. Comi (Italy)10.30 Discussion10.45 Coffee breakSESSION II Treatment issues management today - part 1Moderator: G. Comi (Italy)11.10 L5: Do IFNs and GA still have a role in MS?P. Rieckmann (Germany)11.30 L6: Oral drugsL. Kappos (Switzerland)11.50 L7: Antibodies in MSH.P. Hartung (Germany)12.10 L8: When and how to start a therapyT. Ziemssen (Germany)12.30 Discussion12.45 Lunch08.30 Serono Symposia International Foundation (SSIF)Opening and IntroductionG. Comi (Italy), D. Bates (UK),M. Sandberg-Wollheim (Sweden)
  9. 9. 9SESSION IV How to implement recovery processes and brain plasticityModerators: D. Bates (UK) - G. Comi (Italy)15.45 L12: New biological basis of rehabilitationJ.A. Kleim (USA)16.05 L13: NeuroprotectionB. Kieseier (Germany)16.25 L14: Cell therapyM. Bacigaluppi (Italy)16.45 L15: The multidisciplinary approachto patient rehabilitationA.J. Thompson (UK)17.05 C3: Case study on rehabilitative approach:treatment to targetSpeaker to be confirmed17.25 KN1: Symptoms managementA.J. Thompson (UK)17.55 Discussion18.10 End of day 1SESSION III Treatment issues management today - part 2Moderators: R. Karabudak (Turkey)M. Sandberg-Wollheim (Sweden)13.45 L9: Long term benefit of current DMDson disability progression: experience fromclinical trials and clinical practiceD. Goodin (USA)14.05 L10: When and how to switchfrom a therapy to anotherG. Comi (Italy)14.25 L11: How to detect and monitor safety issuesA. Siva (Turkey)14.45 C2: Case study presentation on treatmentto target: shared decision makingD. Bates (UK)15.05 Discussion15.20 Coffee break
  10. 10. 10SESSION V Genetics-genomics-proteomicsModerators: D. Bates (UK) - M. Sandberg-Wollheim (Sweden)08.45 L16: Genetics to predict disease risk and evolutionD. Hafler (USA)09.05 L17: Beyond genetics: integrating next generationsequencing based approachesE. Stupka (Italy)09.25 L18: Pharmacogenetics and pharmacogenomicsJ. Oksenberg (USA)09.45 L19: How to translate knowledge into practiceG. Giovannoni (UK)10.05 C4: Case studies presentation on how difficultis to identify the response to treatmentG. Giovannoni (UK)10.25 Discussion10.40 Coffee breakSESSION VI Paediatric MSModerators: D. Bates (UK) - M. Sandberg-Wollheim (Sweden)11.00 L20: Environmental and geneticfactors/clinical phenotypesA. Yeh (Canada)11.20 L21: How difficult is the diagnosisof MS in childrenS. Tenembaum (Argentina)11.40 L22: Treatment recommendationsfor paediatric MSA. Ghezzi (Italy)12.00 C5: Case studies presentation on juvenileMS/differential diagnosisS. Tenembaum (Argentina)12.20 KN2: How to interpret results in MS clinical trialsstatistical issuesM.P. Sormani (Italy)12.50 Discussion13.05 Concluding remarksEnd of the conferenceClosing lunchSaturday, 1 June
  11. 11. VenueThe conference will take place at:Ceylan Intercontinental hotelAsker Ocagi Caddesi No. 1 Taksim34435 Istanbul, TurkeyTel. 0212 368 4444LanguageThe official language of the conference will be English.General information11
  12. 12. 12Registration fees> Full registration fee is € 400,00> Full registration fee for young physicians,up to 35 years old, is € 360,00These fees include:• Scientific sessions• Coffee breaks and luncheons• Dinner on 31 May 2013• Educational materials• Certificate of attendance> Registration fee without dinner is € 320,00> Registration fee for young physicians,up to 35 years old, without dinner is € 280,00These fees include:• Scientific sessions• Coffee breaks and luncheons• Educational materials• Certificate of attendanceFor any registration and/or accommodationrequirement please contact our Organizing Secretariat:Meridiano Congress InternationalCongress coordinator: Federica RussettiTel.: +39 (0)6 88 595 209 - Fax: +39 (0)6 88595 234E-mail: f.russetti@meridiano.itRegister to Serono Symposia International Foundation website:www.neurology.seronosymposia.orgfollow us onhttp://twitter.com/SSIF_Neurology#neurologySSIF_Neurology
  13. 13. Improving the patient’s life through medical educationwww.seronosymposia.orgSerono Symposia International FoundationHeadquarters14 Rue du Rhône - 1204 Geneva, SwitzerlandRepresentative OfficeSalita di San Nicola da Tolentino 1/b - 00187 Rome, ItalyT. +39 (0)6.420.413.1 - F. +39 (0)6.420.413.677Copyright© Serono Symposia International Foundation, 2013. All rights reserved.DESIGN:GENTIL